Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

ASX ANNOUNCEMENT 19 March 2026 Radiopharm to present at NWR Virtual Healthcare Conference Sydney, Australia- 19 March 2026 - Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmace

Key Takeaway: Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced its upcoming presentation at the NWR Virtual Healthcare Conference scheduled for March 25, 2026. The CEO, Riccardo Canevari, will discuss the company’s innovative approaches in oncology radiopharmaceuticals. This event aims to connect Radiopharm with shareholders, investors, and other interested parties. A recording of the presentation will be accessible to the public after the live session.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm is actively engaging with the investment community via a conference presentation.
  • The company is focused on developing innovative oncology radiopharmaceuticals.
  • Radiopharm's clinical pipeline includes advanced therapies for cancer treatment.

Full Press Release Details

to present at NWR Virtual Healthcare Conference
Sydney, Australia- 19 March 2026 - Radiopharm Theranostics
(ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative
oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it will present at the NWR Virtual Healthcare
CEO & Managing Director Riccardo Canevari will present at 8:30am
AEDT on Wednesday 25 March 2026.
Shareholders, investors and interested parties are encouraged to register
to attend the presentation at the following link: https://us02web.zoom.us/webinar/register/WN_WlOvxNAQRImgmoTV07BUsA
A recording will be available at the above link shortly after the conclusion
of the live session, and the replay will also be available via the Company's website and social media channels.
Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au
For more information please visit: https://nwrcommunications.com/healthconf
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics
company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas
of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly
differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program
includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn
more at radiopharmtheranostics.com.
Authorised on behalf of the Radiopharm Theranostics board of directors
by Chairman Paul Hopper.
For more information:
CEO & Managing Director
Radiopharm Theranostics
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
Precision AQ (Formerly Stern IR)
Radiopharm Theranostics
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia

Frequently Asked Questions

When will Radiopharm present at the NWR Virtual Healthcare Conference?

Radiopharm will present on Wednesday, 25 March 2026, at 8:30 AM AEDT.

How can I register for the Radiopharm presentation?

You can register for the presentation via the provided Zoom link.

Will there be a recording of the presentation available?

Yes, a recording will be available shortly after the live session.

What is Radiopharm Theranostics known for?

Radiopharm develops innovative radiopharmaceuticals for cancer therapies.

How many clinical trials is Radiopharm currently conducting?

Radiopharm's clinical program includes one Phase 2 and four Phase 1 trials.

Last updated: Mar 19, 2026